PMC10436545_01
LDL-cholesterol during treatment with different lipid-lowering medications, including simvastatin, atorvastatin, pravastatin, ezetimibe, and bempedoic acid.
fcvm-10-1203832-g001.jpg
PMC10436545_01_fcvm-10-1203832-g001.jpg
F1
Figure 1 shows the serial LDL-cholesterol values between March 2017 and December 2022. However, LDL-cholesterol remained high, measuring 143 mg/dl in October 2018 (Figure 1). During this period from March 2019 to December 2020, LDL-cholesterol remained above the desired target value, ranging between 102 and 124 mg/dl (Figure 1).
CCTA shows a non-calcified plaque and calcified components in the distal RCA of the patient (red and green arrows in A-C, pointing to low-attenuation and calcified plaque components, respectively). The lesion detected in the distal RCA reveals signs of favorable plaque component modification with follow-up CCTA after 20 months, exhibiting similar calcified plaque (green arrows in D-F), whereas low-attenuation plaque components are now hardly detectable (red arrows in D-F).
fcvm-10-1203832-g002.jpg
PMC10436545_01_fcvm-10-1203832-g002.jpg
F2
In the distal RCA, a moderate stenosis was detected, composed of non-calcified calcified components [Figures 2A, C, E, pointing to low-attenuation (red arrows) and calcified (green arrows) plaque components]. Interestingly, the moderate lesion detected in the distal RCA in the baseline scan now revealed signs of plaque stabilization, exhibiting similar calcified plaque (green arrows in Figures 2B, D, F), whereas the low-attenuation plaque component was hardly detectable (small red arrows).